Skip to main content
. 2021 Jan 1;5(2):143–154. doi: 10.7150/ntno.53844

Figure 3.

Figure 3

Regrowth of THJ-16T subcutaneous tumors after withdrawing from docetaxel (DTX) and doxorubicin (DOC) treatment. (A) Tumor volume change (%) and (B) HE histological staining (x 40) of the untreated and docetaxel/doxorubicin-treated groups during and after treatment. The black arrow means the time of CH injection and the green arrow means the time of CH administration completed. **, P < 0.01 with significant difference; the error bars, the mean ± standard deviation (SD).